Urothelial carcinoma of the urinary bladder is a heterogeneous disease with multiple
possible treatment modalities and a wide spectrum of clinical outcome. Treatment decisions …

Background Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical
cystectomy (RC) is the standard of care for patients with muscle-invasive bladder cancer …

Methods All relevant articles on MIBC and metastatic bladder cancer were sought using a
combination of Medline and EMBASE searches. The search strategy involved the following …

Purpose Immunotherapy aimed at inhibiting the PD-1/PD-L1 immune checkpoint has been
approved and used successfully for the treatment of bladder cancer. The identification of …

Background Metastatic urothelial carcinoma (mUC) treated with chemotherapy is associated
with poor survival; however, as the field of immuno-oncology continues to evolve, new …

Background Cisplatin-based neoadjuvant chemotherapy (NAC) before cystectomy improves
survival in muscle-invasive urothelial bladder cancer (MIBC). The use of NAC before …

Background An assessment of surgical risk is essential for patient counseling and decision
making, and it can provide rationale adjustment for patient populations as health care moves …

Background Neoadjuvant chemotherapy is underutilized in bladder cancer patients who
undergo radical cystectomy. However, the quality of regimens used in this setting remains …

Aims With the failure to improve outcomes of patients with bladder cancer over the last 30
years, this study was developed to benchmark contemporary UK radiotherapy practice for …

Objectives To quantify the health‐related quality of life (HRQoL) of patients with bladder
cancer around the time of diagnosis and to test the hypotheses of a two‐factor model for the …